Top stocks for today - 11th November 2024

11 Nov 2024 , 12:08 PM

Here are some of the stocks that may see significant price movement today.

Tata Motors: JLR’s results are hampered by both fluctuating local demand and production restrictions. Net profit was ₹3,343 Crore, down 11.2% from the previous year. Revenue dropped 3.8% to ₹1.01 Lakh Crore. EBITDA fell 12% at ₹12,159 Crore. EBITDA margin fell to 12% from 13.1% last year. JLR’s profitability has been hit by a temporary aluminium supply bottleneck, and 6,029 vehicles have been held for further quality control inspections. JLR expects production and wholesale volumes to increase significantly in Q2. 

Asian Paints: Domestic volumes fall by 0.5%, contrary to expectations of 6-8% growth. Weak consumer sentiment, as well as severe rain and flooding in various parts of the country, had an impact on the results. Revenue has been impacted by price cuts implemented last year, a shift in mix, and increased refunds. Higher material prices and rising sales charges have had an impact on operating profits. Profit was hurt by a ₹124 Crore investment value impairment in White Teak Co and a ₹56 Crore foreign exchange loss in Ethiopia. Demand remains challenging. 

Divi’s Laboratories: Revenue rose 22.5% at ₹2,338 Crore. Net profit increased 47% to ₹510 Crore. EBITDA increased 50% to ₹716 Crore. EBITDA margin increased to 30.6% from 25.1% the previous year. Double-digit revenue growth, fuelled by rising demand for custom synthesis and new generics. Healthy CS sales and a little decrease in other expenses boosted profits. FY25 is likely to have a higher capex of ₹1,600 Crore. The Kakinada project is proceeding, with production scheduled to begin in December 2024.

Aarti Industries: Net profit fell by 43% to ₹52 Crore from ₹91 Crore previous year. Revenue increased by 12% to ₹1,628 Crore, from ₹1,454 Crore last year. EBITDA fell 15.5% year on year to ₹197 Crore. EBITDA margin is 12.1%, down from 16% the previous year.

Metropolis: Net profit increased 31% at ₹47 Crore. Revenue rose 11.5% at ₹349 Crore. EBITDA rose 12.3% to ₹88.5 Crore. EBITDA margin increased to 25.4% from 25.2% the previous year. Patient and test volumes drive revenue growth. B2C revenue growth of 21% was driven by growth in Maharashtra, Speciality, and TruHealth.

Biocon: The United States Food & Drug Association has stated that the Park Site facility in Bengaluru, India, has been classified as Voluntary Action Initiated (VAI). The facility was inspected during July 15 and 16, 2024.

For feedback and suggestions, write to us at [e-mail]